Barcode Diagnostics is developing a “first of its kind” Nanotechnology for personalized cancer drug screening, that quickly and reliably assesses the efficacy of different cancer drugs directly on the tumor within the patient’s own body. Our screening method is based on a proprietary liposome formulation of multiple low-dose chemical and biological anti-cancer agents, and the method for evaluating their activity at real time.
| Website | http://www.barcode-diagnostics.com |
| Employees | 6 (6 on RocketReach) |
| Founded | 2017 |
| Technologies |
JavaScript
,
HTML
,
Twitter
+7 more
(view full list)
|
| Industry | Assisted Living, Health Care, Nanotechnology, Science and Engineering |
| Keywords | Cancer Diagnostics, Nanotechnology, Drug Screening, Drug Efficacy, Personalized Medicine, Tumor Analysis, Precision Oncology, Innovative Diagnostics, Cancer Treatment, Biomedical Technology, Molecular Diagnostics, Oncology Diagnostics, Therapeutic Assessment, Biotechnology, In Vivo Diagnostics, Diagnostic Testing, Pharmaceutical Research, Cancer Research, Healthcare Technology, Medical Technology |
Looking for a particular Barcode Diagnostics employee's phone or email?
Ronen Eavri is the CEO and Co-founder of Barcode Diagnostics.
6 people are employed at Barcode Diagnostics.
Barcode Diagnostics is based in Nazareth, Northern District.